Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O00400

UPID:
ACATN_HUMAN

ALTERNATIVE NAMES:
Solute carrier family 33 member 1

ALTERNATIVE UPACC:
O00400; B2R5Q2; D3DNK4

BACKGROUND:
The Acetyl-coenzyme A transporter 1, identified as Solute carrier family 33 member 1, is essential for importing acetyl-CoA into the endoplasmic reticulum lumen. This function supports the acetylation of ER-based proteins and gangliosides, crucial for maintaining cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Given its association with diseases such as Spastic paraplegia 42, autosomal dominant, and neurodegenerative disorders with congenital cataracts and hearing loss, Acetyl-coenzyme A transporter 1 presents a promising avenue for drug discovery. Targeting this protein could offer new therapeutic strategies for these challenging conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.